KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Cash from Investing Activities (2018 - 2025)

Historic Cash from Investing Activities for Moderna (MRNA) over the last 8 years, with Q3 2025 value amounting to $700.0 million.

  • Moderna's Cash from Investing Activities fell 291.26% to $700.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year decrease of 2538.46%. This contributed to the annual value of $1.9 billion for FY2024, which is 5366.14% down from last year.
  • Per Moderna's latest filing, its Cash from Investing Activities stood at $700.0 million for Q3 2025, which was down 291.26% from $564.0 million recorded in Q2 2025.
  • In the past 5 years, Moderna's Cash from Investing Activities registered a high of $2.0 billion during Q1 2023, and its lowest value of -$3.9 billion during Q1 2022.
  • For the 5-year period, Moderna's Cash from Investing Activities averaged around -$292.1 million, with its median value being $118.0 million (2024).
  • In the last 5 years, Moderna's Cash from Investing Activities tumbled by 2993076.92% in 2021 and then skyrocketed by 51864.41% in 2025.
  • Moderna's Cash from Investing Activities (Quarter) stood at -$1.1 billion in 2021, then rose by 7.91% to -$1.0 billion in 2022, then surged by 48.66% to -$538.0 million in 2023, then fell by 0.19% to -$539.0 million in 2024, then surged by 229.87% to $700.0 million in 2025.
  • Its Cash from Investing Activities stands at $700.0 million for Q3 2025, versus $564.0 million for Q2 2025 and $730.0 million for Q1 2025.